Company intelligence / Profile preview

CELL Technologies Inc.

Ownership: Private
Development stage: Phase 2

Overview

CELL Technologies is a clinical-stage biotech company pioneering stem cell therapy for pain medicine and inflammatory conditions. The company has completed early comparative clinical studies showing robust safety and efficacy—reporting a 60% reduction in pain in arthritis patients, over 85% success in repairing degenerated lumbar discs, and more than 60% of patients stopping opioids after treatment. It is preparing to launch a national pivotal clinical program across Canada following regulatory submissions to Health Canada[3].

Therapeutic areas: RheumatologyNeurology
Modalities: Stem cell therapy (autologous and allogeneic)
Industry: Biotech

Drug pipeline

5 assets

autologous bone marrow cell concentrate

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on CELL Technologies Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CELL Technologies Inc..

Explore the full profile